Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Neushen Therapeutics Inc.

Headquarters: Shanghai, China
Year Founded: 2021
Status: Private

BioCentury | Sep 27, 2024
Market Access

BMS’s new schizophrenia drug has big potential, but won’t be an overnight success

Market access and indication expansion will gate Cobenfy’s ability to help fill the pharma’s major revenue holes
BioCentury | May 18, 2024
Discovery & Translation

Brain-penetrant AAV capsid progress at ASGCT 

Companies and academics showcase two approaches to make AAV capsids with enhanced brain targeting and suppressed liver targeting
BioCentury | Apr 16, 2024
Data Byte

Neumora hold likely more of a setback for company than drug class

At least seven biopharmas have disclosed M4 programs for schizophrenia
BioCentury | Nov 15, 2022
Product Development

Annual BayHelix awards highlight China’s maturing life sciences sector

Legend, Insilico, Turning Point, Immune-Onc among winners; Joan Shen named Woman Leader of Year
BioCentury | Oct 4, 2022
Finance

Oct. 3 Quick Takes: Myovant open to sweeter Sumitovant proposal

Plus Alloy raises series D and updates from Omeros, NeuShen
Items per page:
1 - 5 of 5